Alimera Sciences Stock Price - ALIM

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Alimera Sciences Inc ALIM NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.50 0.00 0.00 0.00 0.50 20:00:00
Bid Price Ask Price Spread Spread % News
0.44 0.475 0.035 7.37% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Alimera Sciences Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 35.50M 71.00M $ -16.38M 0.21 1.60 69.82M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Alimera Sciences News

Loading Messages....

Latest ALIM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALIM Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.440.50.40.4523206k0.0613.64%
1 Month0.47460.50.3210.3904249k0.02545.35%
3 Months0.90.95990.3210.5400220k-0.4-44.44%
6 Months1.061.20.3210.6664149k-0.56-52.83%
1 Year1.061.240.3210.7966124k-0.56-52.83%
3 Years1.631.720.3211.1924219k-1.13-69.33%
5 Years4.966.480.3212.0367248k-4.46-89.92%

Alimera Sciences Description

Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. The product portfolio of the company includes ILUVIEN, which is developed to treat diabetic macular edema. In addition, to the activities related to the development of ILUVIEN, the group is also researching the safety and effectiveness of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors. Geographically it operates through the region of US and also it has its presence in the international market.


Your Recent History
NASDAQ
ALIM
Alimera Sc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.